Abstract
Idiopathic (genetic) epilepsy is a common neurologic disorder of dogs and 25%-30% of these dogs are refractory to antiseizure drug therapy. The purpose of this open-label clinical trial was to evaluate the potential efficacy and tolerability of a traditional Chinese herbal formula Di Tan Tang as an add-on therapy for dogs with refractory presumptive idiopathic epilepsy. Eight dogs with refractory presumptive idiopathic epilepsy were evaluated for seizure frequency 3 months prior to and 3 months after instituting oral Di Tan Tang therapy (0.5g/10lbs body weight, q 12 hrs) using a prospective open-label, non-comparative clinical trial design. The overall mean reduction in seizure frequency after treatment with Di Tan Tang for the 8 dogs was significant (p=0.035) at 27%, with 2 dogs qualifying as responders (≥50% reduction in seizure frequency). One dog experienced mild sedation after starting Di Tan Tang; no other adverse effects were recorded for the remaining dogs. The results of this preliminary investigation suggest that Di Tan Tang may be a useful adjunctive treatment option for dogs with refractory epilepsy. Further clinical investigation into the potential use of Di Tan Tang in canine refractory epilepsy is warranted.
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call